SR ONE Capital Management, LLC, 10% Owner at Avalyn Pharma Inc. (AVLN), bought 555,555 shares at $18.00 ($10.0M) on 2026-05-01, disclosed to the SEC on 2026-05-01.
SR ONE Capital Management, a major shareholder, purchased $5 million of Avalyn Pharma stock at $18.00, marking the largest insider purchase in the company's history. This significant capital commitment suggests the 10% holder sees strong value in the biotech's growth prospects.
The stock is currently trading at $29.84, just 1.19% below its 52-week high of $30.20, indicating the market is pricing in strong recent performance. The shares are also up 14.77% from their 52-week low of $26.00.
Insufficient data — needs manual review
The company is currently unprofitable with a negative forward P/E of -14.05, which exposes the stock to volatility if growth targets are not met. Additionally, the lack of short interest (0.0%) suggests limited downside protection from short covering rallies.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.00 | 277,777 | $5.0M | 50.0% |
| 2 | $18.00 | 277,778 | $5.0M | 50.0% |
| Total | $18.00 avg | 555,555 | $10.0M | 100% |
| Filing → |
| ODTX | SELL | 2026-05-11 | $32K | — | Filing → |
| ZBIO | BUY | 2025-10-14 | $2.4M | — | Filing → |
| ZBIO | BUY | 2024-09-16 | $30.5M | — | Filing → |